Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Regulation of Hematopoietic Stem Cells

Regulation of Hematopoietic Stem Cells

All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Iopanoic acid rapidly restores euthyroidism in refractory thyrotoxicosis pre-thyroidectomy: a retrospective study.

European thyroid journal·2026

Same author

The landscape of microbial associations in human cancer.

Science translational medicine·2025

Same author

Rapidly rising rates of oropharyngeal cancer and economic burden in the UK.

The Lancet. Infectious diseases·2025

Same author

Exploring targets in oropharyngeal cancer - association with immune markers and AI-scoring of B7-H3 expression.

Clinical and translational medicine·2025

Same author

Surgical complications and functional outcomes of 3191 jejunal free flaps used for reconstruction of circumferential defects following head and neck cancer resections: A systematic review.

Oral oncology·2024

Same author

Oropharyngeal cancer: Lack of human papillomavirus awareness and economic burden in the United States.

Clinical and translational medicine·2024

Same journal

Antiangiogenic therapies in gastric cancer: future directions for 2026 and beyond: an UNICANCER gastrointestinal group (UCGI) perspective.

Cancer treatment reviews·2026

Same journal

Treatment of breast cancer brain metastases in the era of novel drugs.

Cancer treatment reviews·2026

Same journal

Standardization of objectives and response criteria for neoadjuvant immunotherapy in resectable squamous cell carcinoma of the head and neck.

Cancer treatment reviews·2026

Same journal

Precision targeting of CLDN18.2: A new therapeutic paradigm for gastric cancer.

Cancer treatment reviews·2026

Same journal

Beyond body surface area: CT-derived body composition as a predictor of chemotherapy toxicity and survival in pancreatic ductal adenocarcinoma: a systematic review.

Cancer treatment reviews·2026

Same journal

Early onset pancreatic Cancer: epidemiology, molecular features, and clinical outcomes.

Cancer treatment reviews·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Apr 15, 2026

From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia

From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia

Published on: October 19, 2014

Langerhans cell sarcoma: a systematic review.

James E F Howard¹, Raghav C Dwivedi¹, Liam Masterson²

¹Department of Otolaryngology, Head and Neck Surgery, Addenbrooke's Hospital, Cambridge, CB2 0QQ, UK.

Cancer Treatment Reviews

|March 26, 2015

Summary

This summary is machine-generated.

Langerhans cell sarcoma (LCS) treatment is challenging due to rarity. Multimodality therapy, including chemotherapy and radiotherapy, shows promise, with surgery crucial for local control and bone marrow transplant for disseminated disease.

Keywords:

Human Langerhans cell histiocytosis Langerhans cell sarcoma Malignant histiocytosis X

More Related Videos

Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis

Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis

Published on: April 12, 2024

Mass Cytometry Analysis of Systemic and Local Immune Responses in Hepatocellular Carcinoma

Mass Cytometry Analysis of Systemic and Local Immune Responses in Hepatocellular Carcinoma

Published on: April 25, 2025

Related Experiment Videos

Last Updated: Apr 15, 2026

From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia

From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia

Published on: October 19, 2014

Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis

Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis

Published on: April 12, 2024

Mass Cytometry Analysis of Systemic and Local Immune Responses in Hepatocellular Carcinoma

Mass Cytometry Analysis of Systemic and Local Immune Responses in Hepatocellular Carcinoma

Published on: April 25, 2025

Area of Science:

Oncology
Hematology

Background:

Langerhans cell sarcoma (LCS) is a rare malignancy with limited treatment evidence.
Optimal therapeutic strategies for LCS remain poorly defined due to its infrequent occurrence.

Purpose of the Study:

To review and analyze clinical data on Langerhans cell sarcoma.
To determine the most effective treatment regimens for LCS based on available evidence.

Main Methods:

Systematic literature search of multiple databases (PubMed, CINAHL, EMBASE, Cochrane, CENTRAL, clinicaltrials.gov, Google Scholar) and hand searching.
Analysis of 46 case series comprising 66 subjects with LCS, extracting data on demographics, treatment, and outcomes.
Statistical analysis of disease-specific survival (DSS) and disease-free survival (DFS) across different disease stages and treatment modalities.

Main Results:

Chemotherapy was the most frequent treatment (71%), followed by surgery (47%).
Multimodality therapy, particularly chemotherapy combined with radiotherapy, demonstrated improved outcomes.
Localized disease conferred a survival advantage; complete surgical excision was effective for local control.
Bone marrow transplant showed promise for disseminated disease, despite toxicity concerns.

Conclusions:

Multimodality treatment approaches are recommended for Langerhans cell sarcoma.
Early adjuvant therapy and timely surgical intervention are crucial for optimal outcomes.
Bone marrow transplantation is a viable option for advanced or disseminated LCS, warranting careful patient selection.